A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Summary

This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). Part 1B is a cohort expansion in 1 or more types of cancer to further evaluate a STRO-004 monotherapy dose, determine the best dose for use in later phases, and examine anti-tumor activity.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Head and Neck Squamous Cell Carcinoma HNSCC
• Non-Small Cell Lung Cancer NSCLC
• Esophageal Cancer
• Gastric Cancer
• Colorectal Cancer
• Pancreatic Ductal Adenocarcinoma (PDAC)
• Cervical Cancer
• Endometrial Cancer
• Urothelial Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Sutro Biopharma, Inc.

Last updated on ClinicalTrials.gov

August 27, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites